These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 34079269)

  • 1. Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients.
    Lee JJ; Memar Montazerin S; Shojaei F; Chi G
    Ther Clin Risk Manag; 2021; 17():471-487. PubMed ID: 34079269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
    Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
    Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
    Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
    Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
    Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
    Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
    Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
    Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
    Garland SG; DeRemer CE; Smith SM; Gums JG
    Ann Pharmacother; 2018 Jun; 52(6):554-561. PubMed ID: 29338293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Betrixaban for prevention of venous thromboembolism in acute medically ill patients.
    Beyer-Westendorf J; Verhamme P; Bauersachs R
    Eur Heart J Suppl; 2018 May; 20(Suppl E):E16-E22. PubMed ID: 29977165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
    Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
    J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological properties of betrixaban.
    Huisman MV; Klok FA
    Eur Heart J Suppl; 2018 May; 20(Suppl E):E12-E15. PubMed ID: 29977164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
    Spyropoulos AC; Raskob GE; Cohen AT; Ageno W; Weitz JI; Spiro TE; Lu W; Lipardi C; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard G; Steg PG; Sugarmann C; Barnathan ES
    Circulation; 2022 May; 145(19):1471-1479. PubMed ID: 35389229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
    Gibson CM; Korjian S; Chi G; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Lopes RD; Gold A; Cohen AT; Harrington RA;
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28698258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs.
    Knotts TL; Mousa SA
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):365-376. PubMed ID: 30809772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
    Snoga JL; Benitez RM; Kim S; Creager O; Lusk KA
    Am J Health Syst Pharm; 2021 Jun; 78(12):1057-1065. PubMed ID: 33580664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes.
    Ageno W
    Intern Emerg Med; 2018 Oct; 13(7):1009-1013. PubMed ID: 28808888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
    Miller KM; Brenner MJ
    Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of betrixaban and its role in clinical practice.
    Lekura J; Kalus JS
    Am J Health Syst Pharm; 2018 Aug; 75(15):1095-1102. PubMed ID: 29941506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
    Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
    J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
    [No Abstract]   [Full Text] [Related]  

  • 18. Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients.
    Santagata D; Cammà G; Donadini MP; Squizzato A; Ageno W
    Expert Opin Pharmacother; 2022 Oct; 23(14):1651-1665. PubMed ID: 36154548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.
    Jamil A; Jamil U; Singh K; Khan F; Chi G
    Crit Pathw Cardiol; 2021 Mar; 20(1):16-24. PubMed ID: 32657973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
    Gibson CM; Chi G; Halaby R; Korjian S; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Gold A; Bandman O; Harrington RA; Cohen AT;
    Circulation; 2017 Feb; 135(7):648-655. PubMed ID: 27881569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.